284 related articles for article (PubMed ID: 25282251)
21. Scleral lenses in the management of ocular surface disease.
Schornack MM; Pyle J; Patel SV
Ophthalmology; 2014 Jul; 121(7):1398-405. PubMed ID: 24630687
[TBL] [Abstract][Full Text] [Related]
22. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome.
Sotozono C; Ang LP; Koizumi N; Higashihara H; Ueta M; Inatomi T; Yokoi N; Kaido M; Dogru M; Shimazaki J; Tsubota K; Yamada M; Kinoshita S
Ophthalmology; 2007 Jul; 114(7):1294-302. PubMed ID: 17475335
[TBL] [Abstract][Full Text] [Related]
23. Functional and visual improvement with prosthetic replacement of the ocular surface ecosystem scleral lenses for irregular corneas.
Lee JC; Chiu GB; Bach D; Bababeygy SR; Irvine J; Heur M
Cornea; 2013 Dec; 32(12):1540-3. PubMed ID: 24145631
[TBL] [Abstract][Full Text] [Related]
24. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy.
De Rojas MV; Dart JK; Saw VP
Br J Ophthalmol; 2007 Aug; 91(8):1048-53. PubMed ID: 17314145
[TBL] [Abstract][Full Text] [Related]
25. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases.
Gregory DG
Ophthalmology; 2011 May; 118(5):908-14. PubMed ID: 21440941
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) scleral lens on visual acuity for corneal irregularity and ocular surface disease.
Parra AS; Roth BM; Nguyen TM; Wang L; Pflugfelder SC; Al-Mohtaseb Z
Ocul Surf; 2018 Apr; 16(2):254-258. PubMed ID: 29425812
[TBL] [Abstract][Full Text] [Related]
27. Quality of life and handling experience with the PROSE device: an Indian scenario.
Bhattacharya P; Mahadevan R
Clin Exp Optom; 2017 Nov; 100(6):710-717. PubMed ID: 28295635
[TBL] [Abstract][Full Text] [Related]
28. PROSE Treatment for Ocular Chronic Graft-Versus-Host Disease as a Clinical Network Expands.
DeLoss KS; Le HG; Gire A; Chiu GB; Jacobs DS; Carrasquillo KG
Eye Contact Lens; 2016 Jul; 42(4):262-6. PubMed ID: 26448446
[TBL] [Abstract][Full Text] [Related]
29. Treatment Modalities and Clinical Outcomes in Ocular Sequelae of Stevens-Johnson Syndrome Over 25 Years--A Paradigm Shift.
Iyer G; Srinivasan B; Agarwal S; Pillai VS; Ahuja A
Cornea; 2016 Jan; 35(1):46-50. PubMed ID: 26555585
[TBL] [Abstract][Full Text] [Related]
30. Prosthetic Replacement of the Ocular Surface Ecosystem Scleral Lens Therapy for Exposure Keratopathy.
Chahal JS; Heur M; Chiu GB
Eye Contact Lens; 2017 Jul; 43(4):240-244. PubMed ID: 27171131
[TBL] [Abstract][Full Text] [Related]
31. Scleral contact lenses in the management of pellucid marginal degeneration.
Rathi VM; Dumpati S; Mandathara PS; Taneja MM; Sangwan VS
Cont Lens Anterior Eye; 2016 Jun; 39(3):217-20. PubMed ID: 26669275
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Gueudry J; Roujeau JC; Binaghi M; Soubrane G; Muraine M
Arch Dermatol; 2009 Feb; 145(2):157-62. PubMed ID: 19221260
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Shanbhag SS; Rashad R; Chodosh J; Saeed HN
Am J Ophthalmol; 2019 Dec; 208():331-341. PubMed ID: 31326519
[TBL] [Abstract][Full Text] [Related]
34. The Boston keratoprosthesis type II: the Massachusetts Eye and Ear Infirmary experience.
Pujari S; Siddique SS; Dohlman CH; Chodosh J
Cornea; 2011 Dec; 30(12):1298-303. PubMed ID: 21963861
[TBL] [Abstract][Full Text] [Related]
35. International Outcomes of the Boston Type I Keratoprosthesis in Stevens-Johnson Syndrome.
Alexander JK; Basak SK; Padilla MD; Yu F; Aldave AJ
Cornea; 2015 Nov; 34(11):1387-94. PubMed ID: 26382898
[TBL] [Abstract][Full Text] [Related]
36. A cross-sectional comparative study on chronic ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series.
Chow LLW; Ng ALK; Chow SSW; Choy BNK; Shih KC; Wong IYH; Chan JCY; Lai JSM
Int Ophthalmol; 2018 Jun; 38(3):1155-1160. PubMed ID: 28547534
[TBL] [Abstract][Full Text] [Related]
37. The Boston keratoprosthesis in Stevens-Johnson syndrome.
Sayegh RR; Ang LP; Foster CS; Dohlman CH
Am J Ophthalmol; 2008 Mar; 145(3):438-44. PubMed ID: 18207122
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19.
Submacular Surgery Trials Research Group
Ophthalmic Epidemiol; 2007; 14(4):205-15. PubMed ID: 17896299
[TBL] [Abstract][Full Text] [Related]
39. The outcomes of corneal sight rehabilitating surgery in Stevens-Johnson syndrome: case series.
Peng R; Chi M; Xiao G; Qu H; Shen Z; Zhao Y; Hong J
BMC Ophthalmol; 2024 May; 24(1):205. PubMed ID: 38711013
[TBL] [Abstract][Full Text] [Related]
40. Treatment of persistent corneal epithelial defect with overnight wear of a prosthetic device for the ocular surface.
Lim P; Ridges R; Jacobs DS; Rosenthal P
Am J Ophthalmol; 2013 Dec; 156(6):1095-101. PubMed ID: 24075432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
